Volume : 11, Issue : 02, February – 2024

Title:

A REVIEW ON NASOPULMONARY DRUG DELIVERY SYSTEM

Authors :

 Ms. SK. Rubin, Sunkesula Sumanth

Abstract :

Nasal drug delivery has received a great deal of attention as a convenient, reliable and promising method for the systemic administration of drugs. This is due to high vascularity, large surface area, the avoidance of hepatic first pass metabolism, gut wall metabolism and/or destruction in gastrointestinal tract. Since nasal mucosa offer several benefits for target delivery, a wide variety of therapeutic compounds may be administered intranasally for topical, systemic and central nervous system action. Pulmonary drug delivery has attracted tremendous scientific and biomedical interest in recent years and has progress considerably within the context of local treatment for lung diseases, by virtue of enhanced local targeting and reduced systemic side effects with the administration of minute drug dosages. The present review is an attempt to provide some information concerning naso-pulmonary drug delivery system such as advantages, disadvantages, mechanism of drug absorption, anatomy of nasal cavity and respiratory tract, factors affecting nasal drug absorption, dosage form, novel drug formulations and recent advancement of nasal delivery system.
The intranasal route has become one of the most explored areas in the field of pharmaceutical research for the delivery of small polar molecules, vaccines, hormones, peptides, and proteins. Due to its high membrane permeability, high vasculature, low enzymatic environment, and avoidance of hepatic first-pass metabolism, this route has been chosen for the systemic distribution of medicines. The enormous surface area of the nasal mucosa promotes non-invasiveness, direct medication transport to the central nervous system (CNS), and rapid commencement of therapeutic impact. The intranasal route can enhance patient convenience, comfort, and compliance because it is practically painless and simple for doctors or patients to administer. This page seeks to provide information about the nasal cavity, its benefits and drawbacks, factors affecting nasal drug absorption, methods to enhance drug absorption, dosage forms, and delivery systems for pharmaceuticals, and some of their applications.
Nasal route of drug delivery has been considered as a potential administration route to achieve faster and higher level of drug absorption because it is permeable to more compounds than the gastrointestinal tract due to lack of pancreatic and gastric enzymatic activity, neutral pH of the nasal mucus and less dilution by gastrointestinal contents.
It is a useful delivery method for drugs that are active in low doses and show no minimal oral bioavailability such as proteins and peptides. One of the reasons for the low degree of absorption of peptides and proteins via the nasal route is rapid movement away from the absorption site in the nasal cavity due to the muco-ciliary clearance mechanism.
Keywords: Naso-Pulmonary drug delivery, mucociliary clearance, nasal, pulmonary, respiratory tract.

Cite This Article:

Please cite this article in press S.K.Rubina et al., A Review On Nasopulmonary Drug Delivery System,, Indo Am. J. P. Sci, 2024; 11 (02).

Number of Downloads : 10

References:

1. A J. Hickev. Pharmaceutical Inhalation Aerosol Technology, 2nd edition, Marcel Dekker, NY, 2004 Alagusundaram M., Deepthi N., Ramkanth S., Angala-parameswari S., Mohamed Saleem T.S., Gnanapra-kash K.. Thiruvengadarajan V. S, Madhusudhana Chetty C, Dry Powder Inhalers – An Overview,Int. J. Res. Pharm. Sci. 2010, 1;1: 34-42
2. Armengot,M., Basterra, Macro,.Rev. Larngol.Octol. Rhinol. 1990, 111,219-226 Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today 2002; 7,18, 967-975.
3. Aulton M.E. ” Pharmaceutics – The science of dosage form design” Churchill Livingston., 494, 2002 Aurora J. Development of Nasal Delivery Systems: A Review.Drug Deliv Technol 2002; 2,7, 1-8.
4. Buri P. Hydrogels destines a la muqueuse nasale. Controle physiologique, Pharm. Acta Helv. 1966,41, 88-101.
5. Chien Y.W., Su K.S.E., Chang S.F., Nasal Systemic Drug Delivery, Ch. 1, Marcel-Dekker, New York, 1-77, 1989
6. Chien YW, Chang SF. Intranasal drug delivery for systemic medications. Crit Rev Ther Drug Carr- Syst 1487401-194.
7. Edman P, Bjork E, Ryden L. Microspheres as a nasal delivery system for peptidedrugs j controlled release, 1992;21:165-72
8. Finlay, Warren Hither mechanics of inhaled pharmaceutical aerosols: an introduction. Boston: Academic Press. ISBN 0-12-256971-7,2001.
9. Franz, M.R., Oth, M.P., U.S patent, 5232704, 1993. Gikuriro S, Bechgaard E. Intranasal administration of insulin to humans. Diabetes kes Clin Prad 1991;12:71-84.
10. Hardy J.C., Lee S.W., Wilson C.G., Intranasal drug delivery by spray and drops, J. Pharm. Pharmacol. 1985, 37, 294-297.
11. Harris A.S., Nilsson I.M, Wagner Z.G, Alkner U., Intranase aommstaton o peotdes, rasa ceooston. biological response and absorption of desmopressin, J. Pharm. Sci. 1986,75, 1085-1088.
12. Hirai, S., Yoshiki, T., Mima, H., Effect of surfactants on nasal absorption of insulin in rats, Int. J. Pharm., 1981,9, 165-171.
13. Hofstee BH. Specificity of esterase. Il.Behavior of pancreatic esterase I and Il toward a homologous series of N-fatty acid esters. J Biol Chem 1952; 199:365-71
14. Hughes B.L., Allen D.L., Dorato M.A., Wolff R.K., Effect of devices on nasal deposition and mucociliary clearance in rhesus monkeys, Aerosol Sci. Technol. 1993,18, 241-249.
15. Hussain A, Hamadi S, Kagoshima M, Iseki K, Dittert L. Does increasing the lipophilicity of peptides enhance their nasal absorption. J Pharm Sci 1991; 80: 1180-1181.
16. Hussain A.A., Hirai S., Bawarshi R., Nasal absorption of natural contraceptive steroids in rats-progesterone absorption, of insulin in rats, Int. J. Pharm., 1981,9, 165-171.
17. Hofstee BH. Specificity of esterase. Il.Behavior of pancreatic esterase I and Il toward a homologous series of N-fatty acid esters. J Biol Chem 1952; 199:365-71
18. Hughes B.L., Allen D.L., Dorato M.A., Wolff R.K., Effect of devices on nasal deposition and mucociliary clearance in rhesus monkeys, Aerosol Sci. Technol. 1993,18, 241-249.
19. Hussain A, Hamadi S, Kagoshima M, Iseki K, Dittert L. Does increasing the lipophilicity of peptides enhance their nasal absorption. J Pharm Sci 1991; 80: 1180-1181.
20. Hussain A.A., Hirai S., Bawarshi R., Nasal absorption of natural contraceptive steroids in rats-progesterone absorption, russanza.rosen.alas. resthad.batennorsuk Jone M. Nasal absorption of propranolol in humans. J Pharm Sci 1980; 69:1240-1243.
21. Hussain MA, Koval CA, Shenvi AB, Aungst BJ, Recovery of rat nasal mucosa from the effects of aminopepti-dase inhibitors. J Pharm Sci 1990;79:398-400
22. Illum L. In: Mathiowitz E, Chickering DE, Lehr CM Ed, Bioadhe- sive formulations for nasal peptide deli-very: Fundamentals, Novel Approaches and Devel-opment. Marcel Dekker. New York; 507-539,1999.
23. Illum L., Drug delivery systems for nasal application, S.T.P. Pharma 1987, 3, 594-598.
24. Illum L., Jorgensen H., Bisgaard H., Krogsgaard O., Ross-ing N., Bioadhesive microspheres as a potential nasal drug delivery system, Int. J. Pharm.,1987,39, 189-199.
25. Inagaki M, Sakakura Y, Itoh H, Ukai K, Miyoshi Y. Ma-cromolecu- lar permeability of the tight junction of human nasal mucosa. Rhinology 1985; 23: 213-221.
26. Inagaki M, Sakakura Y, Itoh H, Ukai K, Miyoshi Y. Ma-cromolecu- lar permeability of the tight junction of human nasal mucosa. Rhinology 1985; 23: 213-221.
27. Jorissen,M., AND Bessems, A., Eur.Arch.Otorhinolar ngol, 1995.252,451-454.
28. Junginger HE. Mucoadhesive hydrogels. Pharmazeu-tische Industrie 1956; 53: 1056-1065.
29. Kadam, S.S., Mahadik, K.R., Pawar, A.P., Paradkar, A.R., Transnasal delivery of peptides – a review, The East.Pharm. July 1993. 47 – 49
30. Kaliner M., Marom Z., Patow C., Shelhamer J, Human respiratory mucus, J. Allergy Clin. Immunol. 1984,73, 318 – 323.
31. Kisan R. Jadhav,Manoj N. Gambhire, Ishaque M. Shaikh, Vilarsrao J. Kadam and Sambjahi S. Pisal, Nasal Drug Delivery System-Factors Aftecting and Applications, Current Drug Therapy, 2007, 2, 27-38
32. M.Alagusundara et al. | Int. J. Res. Pharm. Sci. Vol-1, Issue-4, 454-465, 2010 Kuper CF, Koornstra PJ, Hameleers DM, et al. The role of naso- pharyngeal lymphoid tissue. Immunol Today 1992; 13: 219-224.
33. Lee V.H.L., Enzymatic barriers to peptide and protein absorption, CRC Crit. Rev. Ther. Drug Carrier Syst. Knoch, M. & Finlay, W. H. “Nebulizer Technologies”, Chapter 71 in Modified-Release Drug Delivery Technology, ed. Rathbone/Hadgraft/Roberts, Marcel Dekker, pp. 849-856, 2002
34. Mahalaxmi rathananand, D. S. Kumar, A. Shirwaikar, Ravi kumar, D. Sampath kumar, Preparation of Mu-coadhesive Microspheres for Nasal Delivery by Spray Drying, Indian Journal of Pharmaceutical Sciences, 2007,652.
35.Martin E, Nicolaas GM, Schipper J, Coos V,Frans WH. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Del Rev 1997;29:13-38
36. McMartin C, Hutchinson LE, Hyde R, Peters GE. Analysis of structural requirements for the absorption of drugs and macromole- cules from the nasal cavity. J Pharm Sci 1907; 76: 935-540.
37.Mestecky J, Moldoveanu Z, Michalek SM, et al. Current options for vaccine delivery systems by mucosal routes. I Control Release 1997; 48: 243-257.
38. Michael I. Ugwoke, Remigius U. Agu, Norbert Verbeke, Renaat Kinget, Nasal mucoadhesive drug delivery:Background, applications, trends and future perspec-tives, Advanced Drug Delivery Reviews, 2005, 57, 1640-1665
39. Morimoto K, Miyazaki M, Kakemi M. Effects of proteo-lytic en- zyme inhibition on nasal absorption of salmon calcitonin in rats. Int J Pharm 1995; 133: 1-8.
40. Mygind N., Vesterhauge S., Aerosol distribution in the nose, Rhinology 1978,16, 79-88. Newhouse M.T., Advantages of pressured canister metered dose inhalers, J. Aerosol Med. 1991,4, 139-150.
41. O’Hagan DT, Illum L. Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine. Crit Rev Ther Drug Carrier Syst 1990; 7(1): 35-97.
42. Ohwaki K, Ando H, Watanabe S, Miyake Y, Effects of dose, p” and osmolarity on nasal absorption of secretin in rats, J Pharm Sci 1985;74:550-2
43. Mygind N., Vesterhauge S., Aerosol distribution in the nose, Rhinology, 1978; 16: 79-88.
44. Hughes B.L., Allen D.L., Dorato M.A., Wolff R.K., Effect of devices on nasal deposition and mucociliary clearance in rhesus monkeys, Aerosol Sci. Technol, 1993; 18: 241-249.
45. Alagusundaram M., Deepthi N., Ramkanth S., Angala-parameswari S., Mohamed Saleem T.S., Gnanapra-kash K.. Thiruvengadarajan V. S, Madhusudhana Chetty C, Dry Powder Inhalers – An Overview Int. J. Res. Pharm. Sci, 2010; 1(1): 34-42.
46. Finlay, Warren H.The mechanics of inhaled pharmaceutical aerosols: an introduction. Boston: Academic Press, 2001; ISBN 0-12-256971-7.
48. Newhouse M.T., Advantages of pressured canister me-tered dose inhalers, J. Aerosol Med, 1991; 4: 139-150.
49. Coro DC, Liu JC, Chien YW. Characterization of the barrier properties of mucosal membranes. J Pharm Sci, 1990; 79: 202-206.
50. Bawarshi RN, Hussain A, Crooks PA. Nasal absorption of 17a- ethinyloestradiol in the rat. J Pharm Pharmacol, 1989; 41: 214-215.
51. Lee V.H.L., Enzymatic barriers to peptide and protein absorption, CRC Crit. Rev. Ther. Drug Carrier Syst, 1988; 5: 69-97.
52. Inagaki M, Sakakura Y, Itoh H, Ukai K, Miyoshi Y. Ma-cromolecu- lar permeability of the tight junction of human nasal mucosa. Rhinology, 1985; 23: 213-221.
53. Franz, M.R., Oth, M.P., U.S patent, 1993; 5232704.
54. Jorissen, M., AND Bessems, A., Eur. Arch. Otorhinolar ngol, 1995; 252: 451-454.
55. Arora P, Sharma S, Garg S. Permeability issues in nasal drug deliv- ery. Drug Discov Today, 2002; 7(18): 967-975.
56. Satish BB, adhikrao VY, Amelia MA, Rajkumar M, Bio availability of intranasal drug delivery system, Asian I of Pharmaceutics, 2008; 201-15.
57. Ohwaki K, Ando H, Watanabe S, Miyake Y, Effects of dose, pH and osmolarity on nasal absorption of se-cretin in rats, J Pharm Sci, 1985; 74: 550-2.
58. Gizurarson S, Bechgaard E. Intranasal administration of insulin to humans. Diabetes Res Clin Prac, 1991; 12: 71-84.